Pharma

Purdue's Point of No Return

Purdue's Point of No Return

By

Purdue Pharma's decision to pull its OxyContin sales reps out of doctor's offices highlights what has for years been the biggest part of healthcare marketing budgets. Did we just witness the tipping point?

Sanofi revamps web presence as part of Empowering Life campaign

Sanofi revamps web presence as part of Empowering Life campaign

By

The company is also looking to better combine its web and social media presence.

Five things for pharma marketers to know: Tuesday, February 13, 2018

Five things for pharma marketers to know: Tuesday, February 13, 2018

By

Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.

Infographic | Highlighting top healthcare trends

Infographic | Highlighting top healthcare trends

By

There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.

How should pharma mine electronic health records as a data source?

How should pharma mine electronic health records as a data source?

By

At a time when value-based healthcare is a more common objective among stakeholders, EHR data can enable collaboration among payers, providers, health systems, and pharma manufacturers.

PhRMA takes Let's Talk About Cost campaign to the public

PhRMA takes Let's Talk About Cost campaign to the public

By

PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.

Big Predictions: Agency gurus on the future of data in the industry

Big Predictions: Agency gurus on the future of data in the industry

By

We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.

High five: How these companies are leveraging data to engage A-list HCPs

High five: How these companies are leveraging data to engage A-list HCPs

By

In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.

Cost over sight? Spark's blindness cure has the industry talking

Cost over sight? Spark's blindness cure has the industry talking

By

Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model

W2O hires Edelman's Rita Glaze to lead value, pricing, market access practice

W2O hires Edelman's Rita Glaze to lead value, pricing, market access practice

By

Glaze worked in Edelman's market access practice for more than seven years.

As CAR-Ts go from candidates to brands, what's the marketing strategy?

As CAR-Ts go from candidates to brands, what's the marketing strategy?

By

Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.

MM&M's Data Week: Demystifying one of pharma's biggest pain points

MM&M's Data Week: Demystifying one of pharma's biggest pain points

By

It was at an MM&M event back in late 2013 that I got my first glimpse of how this industry feels about big data.

Pfizer UK public affairs lead joins Edelman

Pfizer UK public affairs lead joins Edelman

Alan Maine has joined Edelman as a senior director in its London health team.

Flexion's pivot proves pain-free

Flexion's pivot proves pain-free

By

Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

By

A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.

Five things for pharma marketers to know: Wednesday, January 10, 2018

Five things for pharma marketers to know: Wednesday, January 10, 2018

By

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

No Google, no problem: Pharma partners with China's tech giants

No Google, no problem: Pharma partners with China's tech giants

By

In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

By

How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

The buyer's guide to pharma, healthcare, and life sciences consultancies

The buyer's guide to pharma, healthcare, and life sciences consultancies

By

Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Merck comms head Adele Ambrose to retire

Merck comms head Adele Ambrose to retire

By

VP of investor relations Teri Loxam will take over Ambrose's role in January.

Five things for pharma marketers to know: Wednesday, December 20, 2017

Five things for pharma marketers to know: Wednesday, December 20, 2017

By

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Gottlieb Eyes Prices, Not Lives

Gottlieb Eyes Prices, Not Lives

It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.

Ironwood strengthens leadership with two new hires

Ironwood strengthens leadership with two new hires

By

The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

By

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

How will the pharma industry fare in 2018 under Trump?

How will the pharma industry fare in 2018 under Trump?

By

The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.

The 2018 pipeline report: Aspiring assets to keep an eye on

The 2018 pipeline report: Aspiring assets to keep an eye on

By

The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

6 Corporate Pharma Sites that Offer Strong User Experiences

6 Corporate Pharma Sites that Offer Strong User Experiences

It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.